Search
Madrigal Pharmaceuticals Inc
MDGLAdd to Watchlist
399.630USD
-0.470-0.12%
Close 11-06 16:00（ET）
9.23BMarket Cap
LossP/E TTM
After-hours 17:31 (ET)402.950USD+3.210+0.80%
After-hours 17:31 (ET)Today
-0.12%
5 Days
-7.14%
1 Month
-19.50%
6 Months
-25.96%
Year to Date
-31.38%
1 Year
-18.21%
Key Figures
400.000Open
401.610High
120.55KVolume
LossP/E TTM
40.77P/E Dynamic
--Dividend TTM
0.52%Turnover Ratio
400.100Prev. Close
378.275Low
46.95MTurnover
LossP/E Static
14.72P/B
0.00%Div Yield TTM
-27.83%ROA
615.00052wk High
0.11Volume Ratio
-465.89MNet Profit
23.10MShares
-13.6314EPS TTM
-1.06Beta
-49.35%ROE
353.54052wk Low
8.41%Amplitude
91.23%Gross Margin
9.23BMarket Cap
-1.98Reward/Risk
2.72%Risk Rate
Madrigal Pharmaceuticals Inc's Score
-0.01vs previous score
Forecast8.40
Financial Health8.58
Technical4.86
Valuation Dimensions9.70
Institutional Confidence10.00
Risk Assessment7.69
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Madrigal Pharmaceuticals Inc Technical Analysis
Technical Indicators
Strong sell
Summary
Strong sell
Moving Average
Strong sell
Madrigal Pharmaceuticals Inc Latest Earnings Call Transcripts
Madrigal Pharmaceuticals (MDGL) Q3 2026 Earnings Call: Rezdiffra Sales Rise 50%
Madrigal Pharmaceuticals Q3 2026 earnings call: Rezdiffra sales rose 50% to $431.3 million, active patients topped 55,800, and net income reached $55.4 million.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
1.90/-0.88
Revenue / Forecast
431.27M/404.26M
Madrigal Pharmaceuticals Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolMDGL
Number of employees528
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Baker Bros. Advisors LP | 9.29% |
| RTW Investments L.P. | 8.65% |
| Avoro Capital Advisors LLC | 7.84% |
| Paulson & Co. Inc. | 7.41% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor/Hedge Fund | 44.46% |
| Investment Advisor | 31.54% |
| Hedge Fund | 14.87% |
| Family Office | 7.43% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51290.600
-208.500 (-0.41%)
26964.500
+329.300 (+1.24%)
7380.000
+23.100 (+0.31%)
12797.000
-1.000 (-0.01%)
58142.000
+876.000 (+1.53%)
6140.600
-37.200 (-0.60%)
89.857
-0.176 (-0.20%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4065.670
-33.020 (-0.81%)
FAQs
What is the current price of Madrigal Pharmaceuticals Inc (MDGL)?
The current price of Madrigal Pharmaceuticals Inc (MDGL) is 399.63.
What is the symbol of Madrigal Pharmaceuticals Inc?
The ticker symbol of Madrigal Pharmaceuticals Inc is MDGL.
What is the 52-week high of Madrigal Pharmaceuticals Inc?
The 52-week high of Madrigal Pharmaceuticals Inc is 615.00.
What is the 52-week low of Madrigal Pharmaceuticals Inc?
The 52-week low of Madrigal Pharmaceuticals Inc is 353.54.
What is the market capitalization of Madrigal Pharmaceuticals Inc?
The market capitalization of Madrigal Pharmaceuticals Inc is 9.23B.
Is Madrigal Pharmaceuticals Inc (MDGL) currently rated as Buy, Hold, or Sell?
According to analysts, Madrigal Pharmaceuticals Inc (MDGL) has an overall rating of Buy, with a price target of 684.95.
What is the Earnings Per Share (EPS TTM) of Madrigal Pharmaceuticals Inc (MDGL)?
The Earnings Per Share (EPS TTM) of Madrigal Pharmaceuticals Inc (MDGL) is -13.63.